ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population

 
• By Dexter Jie Yan
  
Akeso is aiming at both PFS and OS superiority for certain lung cancer patients with a combination therapy comprising ivonescimab and chemotherapy. (Shutterstock)

More from Clinical Trials

More from R&D